Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management
New funding will support the company’s rapid growth trajectory and efforts to transform pharmaceutical supply chains with its advanced biomanufacturing platform.
- 05 06 2025
- |